TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01062841

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Infection Control
Description: Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers.
Study: NCT01205802

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MHV reconstruction
Description: MHV reconstruction with PTFE or homograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MHV reconstruction
Description: MHV reconstruction with PTFE or homograft
Study: NCT04059523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S6G5T-3
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retin-A® 0.1% Cream
Description: once daily
Study: NCT01188148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 5 mg per day of memantine
Study: NCT01755559

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine
Description: antimalarial ACT
Study: NCT03879265

Intervention type: DIAGNOSTIC_TEST
Intervention: Noninvasive chromosome screening
Description: Screening based on MALBAC-NGS technology
Study: NCT01188148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02952963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Study: NCT00343083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux, Paclitaxel & Carboplatin
Description: Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
Study: NCT03112967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-volume preparation, oral sulfate solution
Description: Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: large-volume preparation, 4L polyethylene glycol
Description: 4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
Study: NCT02834208

Intervention type: GENETIC
Group type: OTHER
Intervention: quantitative measures of mRNA

Intervention type: GENETIC
Group type: OTHER
Intervention: quantitative measures of mRNA

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: quantitative measures of mRNA

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment
Study: NCT03062618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablet(s) administered with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablet(s) administered with water
Study: NCT02834208

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Study: NCT03062618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRCL-02
Description: Oral tablet(s) administered with water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administered with water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administered with water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administered with water
Study: NCT03088631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will receive corn-flour placebo tablets (three tablets daily).
Study: NCT03466138

Intervention type: DEVICE
Intervention: PMD-200
Description: The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
Study: NCT02728960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI of the Brain (No Contrast) Scan
Description: DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI of the Brain (No Contrast) Scan
Description: DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI of the Brain (No Contrast) Scan
Description: DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
Study: NCT03286946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: block with Blunt-type block needle.
Description: Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: block with sharp-type block needle.
Description: Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
Study: NCT03410797

Intervention type: DEVICE
Group type: OTHER
Intervention: Inclusion of semi-occluded mask in voice therapy
Description: Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
Study: NCT00463983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Study: NCT00408096

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Copeland or Global CAP resurfacing prosthesis
Description: Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Copeland or Global CAP resurfacing prosthesis
Description: Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
Study: NCT03279913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback training in association with TMS.
Description: EEG-neurofeedback training in association with TMS.
Study: NCT02608580

Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Study: NCT00132795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily monitoring of alcohol & drug use, & therapy skills
Description: Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: standard care (no added treatment)
Study: NCT03032653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Rehabilitation
Description: Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation
Description: Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
Study: NCT03885765

Intervention type: DIAGNOSTIC_TEST
Intervention: Predictive data
Description: The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total.

Intervention type: DIAGNOSTIC_TEST
Intervention: Predictive data
Description: The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total.

Intervention type: PROCEDURE
Intervention: Lung resection
Description: Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
Study: NCT01533285

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Salmonella typhi vaccine (Typhim Vi)
Description: Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
Study: NCT02876315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Redoxon VI
Description: Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
Study: NCT03665233

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR
Description: People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
Study: NCT01365468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: oral daily dosing of tablet starting with 2.5 mg
Study: NCT04461457

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 211-astatine MX35 F(ab')2
Description: Alpha emitting radionuclide 211At conjugated to monoclonal antibody MX35 F(ab')2. Targeting the sodium phosphate transporter (NaPi2b).
Study: NCT00523744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine+valsartan
Description: Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
Study: NCT02405676

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone,Vincristine, Cyclophosphamide
Description: Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone,Vincristine, Cyclophosphamide
Description: Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
Study: NCT03885765

Intervention type: PROCEDURE
Intervention: Lung resection
Description: Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
Study: NCT03831880

Intervention type: DRUG
Group type: OTHER
Intervention: Genotropin
Description: Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Genotropin
Description: Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily

Intervention type: DRUG
Group type: OTHER
Intervention: somatrogon
Description: 0.66 mg/kg/week given subcutaneously once weekly

Intervention type: DRUG
Group type: OTHER
Intervention: somatrogon
Description: 0.66 mg/kg/week given subcutaneously once weekly
Study: NCT02405676

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: 375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
Study: NCT03314259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
Study: NCT02822274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-70_R84-064)
Study: NCT00519220

Intervention type: OTHER
Intervention: Symptom questionnaire
Description: Patients will answer questionnaires evaluating their symptoms of achalasia.
Study: NCT01341574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prism adaptation with optical shift of 10 degrees.
Description: Prism adaptation with optical shift of 10 degrees.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prism adaptation with optical shift of 10 degrees.
Description: Prism adaptation with optical shift of 10 degrees.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prism adaptation with optical shift of 10 degrees.
Description: Prism adaptation with optical shift of 10 degrees.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prism adaptation optical shift of 0 degrees.
Description: Prism adaptation with optical shift of 0 degrees.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Prism adaptation optical shift of 0 degrees.
Description: Prism adaptation with optical shift of 0 degrees.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with:Paracetamol
Description: A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions.
Study: NCT03314259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
Study: NCT02504411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Assisted Colonoscopy
Description: This will be similar to the standard colonoscopy except the endocuff device will be used.
Study: NCT02504411

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: No endocuff device will be used on the study participants undergoing standard colonoscopy.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Furosemide